



9th Congress Edition Novotel PARIS Tour Eiffel





What genetic abnormalities should we search for after a sudden death?

Dr Estelle GANDJBAKHCH

Hôpital Pitié salpêtrière Rythmologie Centre de référence pour les maladies cardiaques héréditaires

www.rhythmcongress.com



Disclosure

I have the following potential conflicts of interest to report:

Consulting: Sorin, Medtronic, Boston






Sports-Related Sudden Death in the General Population

11

Eloi Marijon, Muriel Tafflet, David S. Celermajer, Florence Dumas, Marie-Cécile Perier, Hazrije Mustafic, Jean-François Toussaint, Michel Desnos, Michel Rieu, Nordine Benameur, Jean-Yves Le Heuzey, Jean-Philippe Empana and Xavier Jouven


Circulation. 2011;124:672-681; originally published online July 25, 2011;



Distribution by age of sports-related sudden deaths (SDs) in the overall population (blue) and among young competitive athletes (red).

Marijon E, et al. Circulation 2011


Necropsy study: SCD causes according to age



Semsarian et al. EHJ, 2015 review

47

SCD in athletes (> 3 hours per week) : UK series Arthuthmias & Heart Failure




Finocchiaro et al. JACC 2016

Risk of cardiovascular disease in family members of young sudden cardiac death victims

Denmark 2000-2006 n=470 SD Screening and follow-up of 3073 relatives

Risk of any cardiovascular disease in relatives of young first degree relatives



Ranthe et al. EHJ


Importance of a complete clinical screening in patients with USCD (Casper study)




Unexplained SCD:

normal cardiac function on echocardiogram, no evidence of coronary artery disease, and a normal ECG

63 USCD (mean age=43 Y)






Diagnosis in 56% of patients

LQTs: 8 patients CPVT: 8 patients ARVC: 6 patients Early repolarisation: 5 patients Coronary Spasm: 4 patients Brugada: 3 patients Myocarditis: 1 patient

Clinical screening of 64 relatives \rightarrow 24% (n=15) positives

Krahn et al., Circulation 2009



Diagnostic yield of clinical and genetic screening of relatives (CASPER)



398 Relatives of 212 USCD victim (negative of no post mortem analysis)


- ECG
- Exercice test
- TEE
- SA ECG
- Ajmaline challenge if suspect BrS ECG/ER or nocturnal SCD
- epinephrine challenge if non diagnosis exercice test and exercise induced SCD
- MRI if suspect cardiomyopathy

Identification of possible cause in 120 relatives (30%) Including 17% with probable/definite diagnosis

Mutation in only 5% relatives (targeted testing)

+

Targeted genetic testing if positive phenotype Bs: *SCN5A*, ARVC: *PKP2-DSP*, CPVT: *RYR2*, LQT: 5 genes



Molecular autopsy




=Post mortem genetic screening

Analysis impossible from hair Difficult from parrafin blocks

Blood samples before death


Necropsy tissue (liver++)



Legal issues

- Rightholder consent ++
- Result to right holder

Targeted post mortem genetic screening in cardiomyopathy: Case series from GHPS




→ 15 mutations in 15 patients were identified out of 35 patients (43%)

Marey, Charron et al. GHPS data



Post mortem screening of KCNQ1, KNCH2, SCN5A, RYR2 in unexplained SCD → mutation yield: 15% of cases

Gene Name	Encoded protein	Disease	% of disease	% of SADS ^a
KCNQ1	l _{Ks} K ⁺ channel α-subunit	LQTS1	35-40	10–15
KCNH2	I _{Kr} K ⁺ channel α-subunit	LQTS2	30-35	1–5
SCN5A	I _{Na} Na ⁺ channel α-subunit	LQTS3 BrS	5–10 15–25	<1 <1
RYR2	Ryanodine receptor	CPVT1	60-65	10–15



Semsarian et al. EHJ, 2015 review Andersen et al. Circ genetics, 2016 Post mortem genetic screening in USCD



Genetic screening identifies a high proportion of mutations in patients with idiopathic ventricular fibrillation and sudden cardiac death

Vincent Probst (1), Solena Le Scouarnec (2), Florence Kyndt (3), Jean-Jacques Schott (2), Jean-Baptiste Gourraud (1), Frederic Sacher (4), Philippe Mabo (5), Matilde Karakachoff (2), Stéphanie Bonnaud (2), Jade Violleau (2), Eloi Marijon (6), Florence Dumas (6), Alain Cariou (6), Estelle Baron (2), Pierre Lindenbaum (2), Xavier Jouven (6), Richard Redon (2)

(1) CHU Nantes, Nantes, France – (2) CHU Nantes, Institut du Thorax, INSERM UMR 1087, Nantes, France – (3) CHU Nantes, Institut du Thorax, Nantes, France – (4) CHU Bordeaux, Bordeaux, France – (5) CHU Rennes, Rennes, France – (6) Paris Sudden Death Expertise Center INSERM U970, Paris, France

Abstract 0185-Table

	Cohort 1 (n=75)	Cohort 2 (n=99)
SCN5A	7 (9%)	0
HCM and DCM genes	22 (29%)	17 (17%)
ARVD/C genes	4 (5%)	3 (3%)
LQTS genes (excluding SCN5A)	4 (5%)	4 (4%)
CPVT genes (excluding SCN5A)	7 (9%)	3 (3%)
BRS genes	3 (4%)	1 (1%)
Other	3 (4%)	2 (2%)


Limit of large genetic screening: interpretation of rare missense variants? \rightarrow EXAC database, prediction sofware, Study of familial segregation +++

Long term follow-up after USCD

Τī



79 patients with USCD \rightarrow median FU =10 Y Identification of cause in 20% of cases



	-		
AKAP9	CASQ2	DSP	KCNE2
KCNJ8	RYR2	SNTA1	ANK2
CAV3	GPD1L	KCNE3	KCNQ1
SCN1B	TGFB3	CACNA1C	DES
HCN4	KCNH2	LMNA	SCN3B
TMEM43	DSC2	JUP	KCNJ2
DSG2	KCNE1	KCNJ5	PLN
CACNA2D1	РКР2	SCN4B	CACNB2
SCN5A	DPP6 (VF risk haplotype only)		

Pathogenic mutation in 15% (n=12) GVUS in13 patients

Familial screening and long term follow-up ++

Visser et al, Circ EP, 2016



